Antares Pharma To Host Second Quarter 2012 Earnings Call
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its
second quarter 2012 financial results before the market opens on
Wednesday, August 8, 2012, and host a conference call shortly thereafter
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2012 financial results before the market opens on Wednesday, August 8, 2012, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, Executive Vice President, Chief Financial Officer, and President of the Parenteral Products Division, will host the call. Interested parties may participate in the conference call by dialing 800-762-8779 (US) or 480-629-9722 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on August 22, 2012 by dialing 800-406-7325 (US) or 303-590-3030 (international), and entering the access code 4555567. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com. About Antares Pharma Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet ® and Zomajet ® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin ® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton ® hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) marketed by Watson Pharmaceuticals, Inc. in the U.S. Antares’ portfolio includes Elestrin ® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.